Category Archives: Stell Cell Research


Stem Cell Clinic > Stell Cell Research

Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025

By Stell Cell Research

TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 first quarter earnings conference call on Thursday, May 8, 2025 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.

More here:
Cronos Group Inc. to Hold 2025 First Quarter Earnings Conference Call on May 8, 2025

ORYZON Raises €30 Million in Capital Increase

By Stell Cell Research

MADRID and CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion of a €30 million capital increase through the issuance of 12,765,958 new shares, priced at €2.35 per share. This pricing reflects a 15.44% discount to the 5-day volume-weighted average price (VWAP) of €2.779 per share prior to April 22, 2025, and a 19.38% discount to the April 22 closing price of €2.915. The offering, which was structured as straight equity with no warrants attached, attracted strong demand and was significantly oversubscribed. A US-based institutional investor anchored the round with a €15 million order, with the remaining demand filled by investors across the US, Europe, and Spain. The capital increase was capped at €30 million by the company’s Board of Directors.

Continue reading here:
ORYZON Raises €30 Million in Capital Increase

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

By Stell Cell Research

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Originally posted here:
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform

By Stell Cell Research

ALISO VIEJO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced that 18-month data from the first-in-human study of the SpyGlass Drug Delivery Platform demonstrated improvements in both visual acuity and intraocular pressure (IOP) outcomes, key objectives for long-term treatment of glaucoma or ocular hypertension. The data will be highlighted in a poster presentation at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 25-28, 2025, in Los Angeles.

View original post here:
SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

By Stell Cell Research

WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present data supporting the company’s first-in-class retainagogue, IBSRELA® (tenapanor), as well as results from the IBS in America 2024 supplemental survey, at the upcoming Digestive Disease Week Conference (DDW), to be held May 3-6, 2025, in San Diego. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults.

Read more:
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

By Stell Cell Research

>8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data available >8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data available

Read more here:
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas

←